SARASOTA, FL — December 30, 2025 — Leads & Copy — Silo Pharma Inc. (Nasdaq: SILO) has entered into a non-binding Letter of Intent (“LOI”) with Allucent (US) LLC (“Allucent”), a global clinical research organization, for clinical research services for two planned Phase 1 studies evaluating its SPC-15 nasal spray in healthy subjects.
The studies include an Open-Label, Single Ascending Dose (SAD) study and an Open-Label, Multiple Ascending Dose (MAD) study.
Allucent and Silo intend to negotiate a Master Services Agreement and project-specific Work Order to cover a comprehensive scope of activities across clinical operations, pharmacovigilance, data management, biostatistics, clinical pharmacology modeling & simulation, and medical writing to support execution and reporting of the Phase 1 program. The LOI also outlines proposed payment conditions, including an upfront amount for direct service fees and pass-through costs that would be reconciled against final project invoices.
Silo Pharma is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments. The company’s therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Silo’s research is conducted in collaboration with leading universities and laboratories.
SPC-15 is an investigational intranasal serotonin 5-HT4 receptor agonist being developed by Silo Pharma for stress-induced psychiatric conditions, primarily Post-Traumatic Stress Disorder (PTSD) and anxiety, using a special soft mist nasal spray delivery system for fast brain action. It’s in preclinical stages, partnering with Columbia University, and aims for an accelerated FDA approval pathway (505(b)(2)) by leveraging biomarkers and novel delivery.
“This letter of intent with Allucent could lead to a meaningful step forward in advancing SPC-15 into Phase 1 clinical development,” said Eric Weisblum, Chief Executive Officer of Silo Pharma. “Their global CRO expertise and integrated clinical capabilities appear to align well with our goal of efficiently generating high-quality safety and pharmacokinetic data. We believe this collaboration will allow us to execute our SAD and MAD studies with rigor and speed. Advancing SPC-15 remains a key priority as we strive to build long-term value across our pipeline.”
Contact:
800-705-0120
investors@silopharma.com
Source: Silo Pharma
